FTSE 100 Live: UK Stocks to Edge Higher as New Tariff Threats Swirl
These new levies look pretty steep: Trump said drug companies could face a tax as high as 200% on imports if they didn't move production to the US in the next year.
Keep an eye on stocks like AstraZeneca and GSK, though note that there have been consistent threats around possible pharma tariffs in recent months which haven't materialised, at least not yet. That might mean some of that risk is already priced in.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Digital Transformation Expert Sabine Bennett Joins FTI Consulting's Healthcare & Human Services Practice in Australia
SYDNEY, July 28, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Sabine Bennett as a Senior Managing Director in the Australian Healthcare & Human Services practice. Ms. Bennett, who is based in Sydney, has more than 16 years of experience delivering large, complex, technology-enabled transformation programs for health, aged care and life sciences clients. In her role at FTI Consulting, she will bring her deep sector expertise to help clients strategise, design and deliver digital solutions that improve patient and clinician experience, while working side-by-side with clients to embed these solutions and unlock their full value. 'Sabine has an excellent track record of working with organisations to create seamless digital experiences for consumers, providers and regulators,' said Nathan Schlesinger, Leader of the Healthcare & Human Services practice in Australia at FTI Consulting. 'Her strength lies in driving strategy to execution, delivering the right outcomes by putting people at the centre, while creating value for organisations.' The Healthcare & Human Services industry practice focuses on supporting clients with key industry agendas including sector reform and sustainability, digital transformation and productivity. The practice launched in January 2025 and has continued to add talent to build an industry-oriented capability that complements existing FTI Consulting services in policy and economics, cybersecurity, financial sustainability, restructuring and risk-oriented services. Commenting on her appointment, Ms. Bennett said, 'Australian organisations have great ambitions around Digital and AI to thrive in current conditions, but the execution is often challenging. I am excited to be scaling a practice with the skills and expertise our country needs to lead and support organisations through this. I can't wait to collaborate with my new colleagues as we work with health services and agencies to design and deliver digital solutions that work for patients, clinicians and communities.' Prior to joining FTI Consulting, Ms. Bennett was a Partner and the Digital Health Leader at a Big Four firm in Australia. Prior to that, she worked at NTT DATA Business Solutions, an IT services and consulting firm. About FTI Consulting FTI Consulting, Inc. is a leading global expert firm for organisations facing crisis and transformation, with more than 7,900 employees located in 32 countries and territories as of June 30, 2025. In certain jurisdictions, FTI Consulting's services are provided through distinct legal entities that are separately capitalised and independently managed. The Company generated $3.70 billion in revenues during fiscal year 2024. More information can be found at FTI Consulting, 22, Gateway1 Macquarie PlaceSydney, NSW 2000Australia+61 2 8247 8000 Investor Contact:Mollie Hawkes+ Media Contact:Rebecca Hine+61 402 235 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Bristol Myers, Bain Capital form new company to develop immunology drugs
(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the companies said on Monday. The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and a mid-stage psoriasis drug that has shown promise in trials. Bristol Myers will retain nearly 20% equity in the venture and is set to receive royalties and milestone payments based on the drugs' success. The collaboration allows the drugmaker to concentrate its immunology research on treatments aimed at resetting the immune system while ensuring the continued development of promising assets, the companies said. "These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients," said Julie Rozenblyum, senior vice president of business development at Bristol Myers. Daniel Lynch, a seasoned pharmaceutical executive, will take on the roles of executive chairman and interim CEO of the new company, while Bristol Myers' chief research officer Robert Plenge is set to join the board alongside Bain Capital partners. Canada Pension Plan Investment Board also participated in the financing round. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
8 minutes ago
- CNN
What are your questions about lifestyle changes and cognitive decline?
Food & health Chronic diseases Dementia Getting olderFacebookTweetLink Follow Healthy habits like eating a nutritious diet and getting regular exercise can protect your brain as you age. Research shows that it may even help after physical signs of cognitive problems begin. What do you want to know about how your lifestyle might affect your risk of cognitive decline, including conditions such as Alzheimer's disease? Share your questions with CNN below.
